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HPV-Positive Oral Squamous Cell 
Carcinoma
Șerban Vifor Gabriel Berteșteanu, Raluca Grigore, 
Alexandru Nicolaescu and Mihnea Cojocărița-Condeescu
Abstract
Head and neck malignancies represent the sixth most frequent type of cancer 
currently in worldwide statistics. Of these, oral and pharyngeal cancers have 
steadily increased, being linked with the increase in HPV infection pandemic. This 
rise is not due to one cause, but rather multiple factors such as lifestyle and sexual 
behavior pattern changes and globalization. Because of the anatomy of the oral 
cavity and oropharynx, the proper diagnosis is easily delayed, and patients present 
with advanced stage disease, which requires aggressive and extensive surgery along 
with neck dissection and chemoradiotherapy. Patients with advanced stage disease 
have a high recurrence risk with a low 5-year survival rate. Preventing the HPV 
infection is of course desirable, but right now, for adults which already are infected 
and have a higher risk of developing HPV-related neoplasias, as well as for our head 
and neck cancer patients, alternative treatment algorithms are necessary.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
malignancy in the world [1]. The tonsils are the most common location in oropha-
ryngeal malignancy. Despite being easily accessible to examination, its symptoms 
are usually ignored especially in early stages, leading to high morbidity and mor-
tality. Traditionally oral and oropharyngeal cancers were attributed to smoking 
and alcohol abuse, but in more recent years there has been an increase in numbers 
due to high prevalence of human papillomavirus (HPV) infection. The presence of 
HPV can alter the prognosis of the disease, and recently there was a change in the 
WHO classifications and TNM staging to reflect this [2]. Depending on the stage 
of the disease, treatment for oral and oropharyngeal cancers consists of surgery 
and/or chemoradiotherapy.
2. Etiology
Traditionally smoking is considered the major factor in developing tonsil cancer. 
More than three quarters of oropharyngeal cancers are associated with tobacco use 
in all its forms (cigarettes, cigars, pipes, chewed tobacco). Secondhand smokers also 
have an increased risk of developing head and neck cancers. Alcohol is the second 
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major risk factor in the etiology of tonsil cancer. Although studies have not shown a 
direct link between the use of alcohol alone in carcinogenesis, the combined effect 
of tobacco and alcohol has a synergic effect on the development of cancer cells [3].
In the last 10 years, HPV infection has been widely recognized as an important 
etiological factor in the development of head and neck squamous cell carcinomas. 
The development of PCR analysis or in situ hybridization has demonstrated the 
impact of HPV in oropharyngeal malignancy [1]. Gillison [4] was the first to show 
that HPV-positive oropharyngeal cancers have different molecular, clinical, and 
pathological traits than HPV-negative cancers. Although HPV is considered to play 
a vital role in most head and neck cancers, studies have only proven its impact in 
oropharyngeal cancers [5].
HPV is a double-stranded DNA oncovirus and is epitheliotropic, infecting 
the basal cells of the epithelium and can be found in up to 60% of squamous cell 
carcinomas of the oropharynx [6]. There are more than 150 isolated strains of HPV, 
but only two types 16 and 18 are most commonly linked to oropharyngeal cancers. 
The oncogenic effect of HPV is due to two proteins E6 and E7 that target the p53 
and pRB (retinoblastoma) tumor suppressor genes of the infected cells making 
them vulnerable to mutations [7]. The loss of the pRB tumor suppressor deter-
mines the intranuclear accumulation of p16. p16 has a tumor suppressor role which 
normally would inhibit cell cycle but is overexpressed in HPV-positive tumors due 
to the action of E7. It is considered a useful marker in oropharyngeal cancers [8]. 
Due to the large body of evidence that suggest that HPV-positive and HPV-negative 
oropharyngeal cancers represent distinct subgroups of OPSCC, the National 
Comprehensive Cancer Network (NCCN) guidelines as of 2017 require HPV testing 
for all oropharyngeal tumors and that the HPV status must be included as a stratifi-
cation factor [2]. The latest staging for oropharyngeal cancers takes into account the 
distinct groups of OPSCC, and because HPV-positive cancers tend to have a better 
prognosis, separate TNM staging systems are used [9, 10].
Dietary habits also play a role in carcinogenesis although harder to properly 
quantify. For example, iron deficiency may lead to an increased vulnerability of 
the oropharyngeal mucosa and decreased immune system. A diet low in fruits and 
vegetables can lead to a vitamin A and vitamin E deficiency that is associated with 
an increased risk of developing oropharyngeal malignancies. Poor oral hygiene can 
also be a risk factor especially for tobacco and alcohol users [11].
3. Symptoms and diagnosis
Oropharyngeal cancer is usually located in the tonsillar fossa, but extension to 
adjacent structures is common (Figure 1). Frequently tonsillar carcinoma extends 
downward to the tongue base along the glosso-tonsillar sulcus (Figure 2) and to the 
soft palate laterally. Laterally the tonsillar fossa is bounded by the superior constric-
tor muscle of the pharynx which offers some resistance to the spread of carcinoma. 
Extension past the superior constrictor muscle represents involvement of the para-
pharyngeal space with consecutive involvement of the pterygoid musculature or 
mandible locally advanced disease. Extension to the skull base is rare but possible.
Due to its rich lymphatic drainage, lymph node involvement is present in about 70% 
of patients. The most common lymph node levels affected are level II and level III [12].
Distant metastasis from tonsillar cancer occurs in about 15–30% of cases; the 
most common sites are the lung, liver, and bones [13].
Tonsillar cancer may present with a variety of signs and symptoms. In the early 
stages, the patient is usually asymptomatic, or it can mimic some mild diseases like 
sore throat or acute tonsillitis. Patients usually complain of sore throat, unilateral 
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otalgia, or a feeling of a mass in the throat. In advanced stages it can present with 
dysphagia. In latter stages the patient may present with trismus or bleeding from 
the mouth. If the tumor has ulcerations and necrosis, patients will usually complain 
of bad breath. The rich lymphatic drainage could mean that the first sign of disease 
is enlarged lymph nodes especially in the jugulodigastric region (group II). Such 
patients must be asked about weight loss, hoarseness, and odynophagia. A thorough 
patient history about tobacco and alcohol use and other known etiological factors 
(including known HPV infection) may raise suspicion of a malignant tumor. HPV-
positive tumors will typically appear in younger nonsmoking patients.
Patients diagnosed with a tumor involving the oral and oropharyngeal regions 
must undergo a full ENT examination, with neck palpation, flexible endoscopy, and 
biopsy. After histological confirmation of the malignancy, imaging studies must be 
obtained to stage the tumor. Contrast CT scans represent the standard method for 
Figure 1. 
Oral examination of a male patient with a left oropharyngeal tumor which infiltrates and deforms the 
tonsillar fossa as well as part of the soft palate, with ulceration and suprainfection.
Figure 2. 
Fiber-optic endoscopy of a male patient showing inferior spread of a left side oropharyngeal tumor towards the 
tongue base.
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staging and should include the skull base, cervical region, thorax, and abdomen to 
possibly identify secondary tumors. Contrast-enhanced MRI is superior to CT in 
detecting soft tissue extension and involvement but may be influenced by dental 
foreign materials.
Staging of the disease is done by using the AJCC cancer staging system (Table 1) 
that uses three variables—primary tumor characteristics (T), lymph node involve-
ment (N), and the existence of metastases (M).
Starting from 1 January 2017, all patients with oropharyngeal cancer should 
be tested for the presence of HPV, thus classifying them in one of two possible 
categories—HPV positive (p16INK4A+) and HPV negative. There is no current gold 
standard test, because all available testing methods were developed for cervical 
cancer, and not perfectly adapted for tonsillar cancer. However, p16 protein IHC is 
currently used for detecting HPV presence [15].
Tumor Characteristics
T0 No primary tumor identified
T1 Tumor less than 2 cm in any dimension
T2 Tumor between 2 and 4 cm
T3 Tumor greater than 4 cm in any dimension or extension to lingual surface of the 
epiglottis
T4 = moderately advanced local disease—tumor invades the larynx, extrinsic muscles of 
the tongue, medial pterygoid muscles, hard palate, mandible or beyond
Table 2. 
AJCC tumor characteristics regarding HPV-positive (p16+) oropharyngeal carcinoma [14].
Stage T N M
I T0-T2
T0-T2
N0
N1
M0
M0
II T0-T2
T3
N2
N0-N2
M0
M0
III T0-T3
T4
N3
N0-N3
M0
IV T Any N Any M1
Table 1. 
AJCC staging of HPV-positive (p16+) oropharyngeal cancer [14].
Lymph 
node (N)
Clinical N (cN) Pathological N (pN)
Nx Regional lymph nodes cannot be assessed Regional lymph nodes cannot be 
assessed
N0 No regional lymph node metastasis No regional lymph node metastasis
N1 One or more ipsilateral lymph nodes, none 
>6 cm
Metastasis in 4 or fewer lymph nodes
N2 Contralateral or bilateral lymph nodes, none 
>6 cm
Metastasis in more than 4 lymph 
nodes
N3 Lymph node(s) > 6 cm
Table 3. 
AJCC lymph node characteristics for staging of disease regarding HPV-positive (p16+) oropharyngeal cancer.
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Tumor and lymph node characteristics are described in Tables 2 and 3, whereas 
the presence of distant metastases automatically stages the disease into the last and 
most severe stage—stage IV (Table 1).
4. Treatment and outcome
Treatment of oropharyngeal malignancy depends on the disease stage, but the 
principle that guides it is the same as in all cancer surgery: local disease control. 
Thus, with modern surgical and irradiation techniques, 5-year survival rates of 
almost 100% are attainable [16].
For the purpose of management protocol, oropharyngeal cancer is divided 
into early-stage (T1 and T2) and advanced diseases (T3 and T4). The latter are 
divided into resectable and non-resectable tumors. According to this, treatment for 
early-stage disease should be either surgery or radiation therapy with concurrent 
chemotherapy. Surgical treatment consists of excision of the primary tumor, either 
by a trans-oral approach or by external approach (lateral pharyngotomy or trans-
mandibular approach by mandibular swing technique (Figures 3–5)).
Most oropharyngeal tumors are accessible by trans-oral approach. This is the 
least aggressive type of surgical approach, with the least morbidity. Auto-static 
mouth gags (McIver, Dingmann, etc.) permit good exposure of the surgical site, 
and excision by electrocautery, radiofrequency, and CO2 laser, and optical augmen-
tation either using surgical loupes or operating microscopes permit tackling most of 
the T1 to T3 tumors [17].
Tumors extending downward to the epiglottis and hypopharynx (pyriform 
sinus) require an external approach, by lateral pharyngotomy. This approach 
provides access to the oro- and hypopharynx, as well as control of the cervical large 
blood vessels and lymph nodes [18–20].
Advanced tumors (T4), tumors which involve adjacent structures (extrinsic 
muscles of the tongue, larynx, mandible, pterygoid muscles, or hard palate), often 
require an even more aggressive external approach—by lateral mandibulotomy—
the so-called mandibular swing technique. This approach permits access to the 
Figure 3. 
External approach to a right side advanced (T4) oropharyngeal cancer which shows the neck dissection, with 
internal jugular vein and bifurcation of the common carotid artery visible inferior to the posterior belly of the 
omohyoid muscle, as well as the mandibulotomy—The creation of the mandibular “swing.”
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oral cavity, oropharynx, as well as hypopharynx and lateral cervical lymph nodes, 
parapharyngeal space, and masticator space and allows instrumentation of the 
entire oral cavity, making hard palate resections possible [21, 22].
Whichever surgical approach to the primary tumor the surgeon opts for, just 
as important as the complete excision of the tumor (the T) is the neck dissection. 
Tumors that do not pass the midline usually require ipsilateral lymph node dissec-
tion. However, bilateral neck dissection is sometimes required because of the vast 
network of lymphatics that drain the lateral pharyngeal area—most patients present 
with at least clinically N1 on diagnosis [23, 24].
The alternative to surgical excision of the tumor is external intensity-modulated 
radiation therapy (IMRT) with or without adjuvant chemotherapy. This procedure 
has similar outcomes compared to surgery in cases of early-stage tumors but is 
slightly inferior compared to surgery when addressing advanced tumors. The dose 
delivered to the surrounding tissues is responsible for the toxicity and late adverse 
Figure 4. 
External approach to a left side advanced oropharyngeal tumor, via mandibular “swing” demonstrating 
closure of the mandibulotomy using two titanium miniplates anchored with screws.
Figure 5. 
Extensive external approach to a left side advanced (T4) tumor of the oropharynx and hypopharynx 
extending to the bony cortex of the mandible—with modified radical neck dissection and lateral 
mandibulotomy, with the two resulting mandibular pieces being pulled apart at different angles so as to permit 
wider access.
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effects of radiation therapy, such as osteoradionecrosis of the mandible, radiomuco-
sitis, xerostomia, dental cavities, and teeth avulsion [25]. These have a high impact 
on the patients’ quality of life; thus modern management of HPV-positive oropha-
ryngeal cancer consists in trans-oral excision (with a rising trend towards robotic 
surgery) of the primary tumor with selective neck dissection followed by low-dose 
radiation therapy [25].
5. Conclusions
As HPV infection is a growing concern worldwide, cases of HPV-positive oral 
and oropharyngeal carcinoma become more frequently encountered. Treatment 
options for this type of malignancy follow the same principles as for non-HPV-
positive squamous cell carcinoma of the oral cavity and pharynx, consisting in 
surgery for locoregional control of the primary tumor and regional lymph nodes 
and radiation therapy—either as a stand-alone option or as an adjuvant therapy 
following surgical excision.
However, particularities of HPV-positive oropharyngeal cancer have led to a 
separation of this pathologic entity from the rest of squamous cell carcinomas 
involving the oropharynx. These tumors have a better outcome following treatment 
and thus treatment options were de-escalated to offer the same outcome and 5-year 
survival as well as less morbidity and a better quality of life.
New perspectives in treating the chronic HPV infection as well as preventing this 
infection by introducing efficient vaccination programs that target girls and boys 
also offer a positive future perspective on reducing malignancies associated with 
this viral infection, including those affecting the oral cavity and pharynx.
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